Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25003833 | 0.80 | ALDH1A1 (0.42) | HSD17B10RAB9AALDH1A1MAPTCYP1A2 | |
| SCHEMBL14575519 | 0.74 | ALDH1A1 (0.53) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL1833771 | 0.70 | HSD17B10 (0.58) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL21892102 | 0.70 | RAB9A (0.53) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL19240769 | 0.68 | RAB9A (0.49) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL126140 | 0.67 | HSD17B10 (0.54) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL1416169 | 0.67 | HSD17B10 (0.58) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL12370956 | 0.67 | NPC1 (0.55) | HSD17B10NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL13055389 | 0.67 | TAAR1 (0.60) | HSD17B10NPC1RAB9ATAAR1GAA | |
| SCHEMBL9778357 | 0.67 | HSD17B10 (0.57) | HSD17B10NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | HSD17B10 1255/4885NPC1 461/4885RAB9A 2167/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | HSD17B10 1255/4885NPC1 461/4885RAB9A 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.